Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

4 articles from the last 90 days matching "hiv"

Clinical trialUNITERARE2 days ago

New Recruiting Trial: Biofeedback-Assisted Pelvic Floor Rehabilitation for Radiation-Induced Sexual Dysfunction in Cervical Cancer Survivors

Researchers are testing a new treatment to help cervical cancer survivors who have sexual problems after radiation therapy. The treatment uses biofeedback—a technique that helps you learn to control your pelvic floor muscles—combined with physical rehabilitation exercises. This trial is now accepting patients to see if this approach can improve sexual function and quality of life.

WHY IT MATTERSThis trial directly addresses a common but often overlooked side effect of cervical cancer treatment, offering cervical cancer survivors a non-medication option to restore sexual function after radiation therapy.
→ You can act on thiscervical cancerradiation-induced sexual dysfunction
GrantNIH REPORTERMay 11

New NIH Grant: Lysine Methylation as a Novel Regulatory Mechanism of HPV E2 Function — $209K at Unknown Institution

Scientists are studying how a virus called HPV (human papillomavirus) uses a process called lysine methylation to survive in human cells. HPV can cause several types of cancer, including cervical cancer. This research aims to understand how the virus works so doctors can develop better treatments to stop HPV infections before they turn into cancer.

WHY IT MATTERSThis basic research could eventually lead to new non-invasive treatments for high-risk HPV infections, which currently have no effective alternatives to invasive procedures and surgery.
ℹ Good to knowCervical cancerOropharyngeal cancerAnogenital cancer
GrantNIH REPORTERMay 11

New NIH Grant: Adapting the "Do More, Feel Better" intervention for older people living with HIV — $700K at Unknown Institution

Researchers are getting $700,000 to adapt a mental health program called 'Do More, Feel Better' for older people with HIV. More than half of people with HIV in the US are over 50, and they are much more likely to feel depressed than people without HIV. This new program will use peer support and community helpers instead of just doctors, to help more people get the mental health care they need.

WHY IT MATTERSOlder adults with HIV have 2.3 times higher risk of depression than those without HIV, and this adapted intervention could address a critical gap in mental health care access for this growing population.
👁 Watch this spaceHIV
Clinical trialCLINICALTRIALSMar 27

New Clinical Trial: A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (NCT04482309)

Researchers are testing a cancer drug called trastuzumab deruxtecan (T-DXd) in patients with several types of rare and uncommon cancers that have a specific protein marker called HER2. The study includes seven different cancer types in the first part, including bladder, bile duct, cervical, uterine, ovarian, and pancreatic cancers. This drug has already shown promise in breast and stomach cancers, and doctors want to see if it works in these other cancer types too.

WHY IT MATTERSThis trial offers patients with HER2-positive rare cancers like biliary tract, cervical, endometrial, ovarian, and pancreatic cancer access to a targeted therapy that has demonstrated effectiveness in other cancer types—potentially providing a new treatment option where few exist.
💬 Ask your doctorbladder cancerbiliary tract cancercervical cancer

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases